40. Theberge I, Hebert-Croteau N, Langlois A, Major D, Brisson J. Volume of screening mammography and performance in the Quebec population-based Breast Cancer Screening Program.

https://kce.fgov.be/sites/defa (...) (...) [HTML]

39. Theberge I, Hebert-Croteau N, Langlois A, Major D, Brisson J. Volume of screening mammography and performance in the Quebec population-based Breast Cancer Screening Program.

https://kce.fgov.be/sites/defa (...) (...) [HTML]

https://kce.fgov.be/sites/defa (...) [HTML]

The use of Magnetic Resonance Imaging of the Breast for screening of women at high risk for breast cancer.

https://kce.fgov.be/sites/defa (...) (...) [HTML]

Magnetic Resonance Imaging for the detection of breast abnormalities.

https://kce.fgov.be/sites/defa (...) (...) [HTML]

https://kce.fgov.be/sites/defa (...) [HTML]

Application Presentation: A web-based Support System for the belgian Breast Cancer Screening Program(.Powerpoint) by Eddy Husson, Informatique Médicale et Biostatistique, Université de Liège (B)

http://www.health.belgium.be/e (...) (...) [HTML]

Application Presentation: Symposium A web-based Support System for the belgian Breast Cancer Screening Program (.Powerpoint) by Eddy Husson, Informatique Médicale et Biostatistique, Université de Liège (B)

http://www.health.belgium.be/e (...) (...) [HTML]

http://www.health.belgium.be/e (...) [HTML]

Het programma is in overeenstemming met de aanbevelingen van de “European Guidelines for quality assurance in breast cancer screening and diagnosis”.

http://www.brumammo.be/documen (...) (...) [HTML]

Le programme suit les recommandations du «European Guidelines for quality assurance in breast cancer screening and diagnosis ».

http://www.brumammo.be/documen (...) (...) [HTML]

http://www.brumammo.be/documen (...) [HTML]

For more results, go to https://pro.wordscope.com to translate your documents with Wordscope Pro!

European guidelines for quality assurance in breast cancer screening and diagnosis, fourth edition. European Commission (2006).

http://www.inami.fgov.be/care/ (...) (...) [HTML]

European Guidelines for quality assurance in breast cancer screening and diagnosis, fourth edition European Commission (2006).

http://www.inami.fgov.be/care/ (...) (...) [HTML]

http://www.inami.fgov.be/care/ (...) [HTML]

52. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials.

https://kce.fgov.be/sites/defa (...) (...) [HTML]

51. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials.

https://kce.fgov.be/sites/defa (...) (...) [HTML]

https://kce.fgov.be/sites/defa (...) [HTML]

20. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening.

http://kce.fgov.be/sites/defau (...) (...) [HTML]

21. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening.

http://kce.fgov.be/sites/defau (...) (...) [HTML]

http://kce.fgov.be/sites/defau (...) [HTML]

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS ...[+++]

http://kce.fgov.be/sites/defau (...) (...) [HTML]

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS ...[+++]

http://kce.fgov.be/sites/defau (...) (...) [HTML]

http://kce.fgov.be/sites/defau (...) [HTML]

Table 9: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 21 Study ID study

http://kce.fgov.be/sites/defau (...) (...) [HTML]

Table 11: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 22 Study ID study

http://kce.fgov.be/sites/defau (...) (...) [HTML]

http://kce.fgov.be/sites/defau (...) [HTML]

17. Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L, et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization.

http://kce.fgov.be/sites/defau (...) (...) [HTML]

17. Tabar L, Dean PB, Kaufman CS, Duffy SW, Chen HH. A new era in the diagnosis of breast cancer.

http://kce.fgov.be/sites/defau (...) (...) [HTML]

http://kce.fgov.be/sites/defau (...) [HTML]

Anderen hebben gezocht naar : screening naar alcoholmisbruik screening naar depressie screening naar drugmisbruik screening naar gehoorverlies screening naar immunisatiestatus screening naar middelenmisbruik screening naar misbruik screening naar ontwikkeling van kind screening naar ontwikkeling van zuigeling breast for screening

datacenter (28): www.wordscope.be (v4.0.br)

'breast for screening' ->

Date index: 2025-08-22